title icon
Luminary's Pipeline

Non-viral Cell Therapies

  • Luminary is developing a broad pipeline of non-viral cell therapies via in-licensed advancements from notable academic institutions and internally developed IP.
  • Our product pipeline will focus on underserved cancers and autoimmune disorders.
  • We are aggressively pursuing our BAFF CAR-T therapy planning to file an IND with the FDA in Q4 2021
Program Type Indication Research Preclinical Phase 1 Phase 2 & 3
LMY-920
BAFF
CAR-T
B-cell Malignancies
Mantle Cell Lymphoma – Autologous
Mantle Cell Lymphoma – Allogeneic
Autoimmune Disorders
Scleroderma
LMY-232
Multiple Targets
Universal
Receptor
Solid Tumors &
Autoimmune Disorders
title icon
Targeting multiple B cell markers on tumor and inflammatory cells

LMY-920’s BAFF target has the potential to preserve early B cells

Depiction of our proprietary B cell activating factor (BAFF) directed third-generation chimeric antigen receptor (CAR). LMY-920’s BAFF targets multiple B cell markers on tumor and inflammatory cells including the BAFF receptor (BAFF-R), BCMA, and TACI.

Luminary Tx proprietary B cell activating factor